Abstract 659: Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Research

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.AM2015-659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

  2026cites this paper
• A New Hope: Dual Human Epidermal Growth Factor Receptor 2 Blockade and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Amplified Colorectal Cancer – A Case Report and Literature Review

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.

  2025cites this paper
• HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

  2024cites this paper
• Treatment options for HER2-expressing colorectal cancer: updates and recent approvals

  2024cites this paper
• HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.

  2024cites this paper
• Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer.

  2024cites this paper
• Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy

  2024cites this paper
• BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation

  2024cites this paper
• Metastatic colorectal cancer: mechanisms and emerging therapeutics.

  2023cites this paper
• Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.

  2023cites this paper
• Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

  2023cites this paper
• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.

  2023cites this paper
• New developments in targeted therapy for metastatic colorectal cancer

  2023cites this paper
• HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer

  2022cites this paper
• Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer

  2022cites this paper
• Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

  2022cites this paper
• Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

  2022cites this paper
• Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer.

  2022cites this paper
• Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study.

  2022cites this paper
• Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.

  2022cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

  2022cites this paper
• Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

  2022cites this paper
• Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer

  2021cites this paper
• A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

  2021cites this paper
• Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

  2021cites this paper
• Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

  2021cites this paper
• Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

  2021cites this paper
• Performance of capecitabine in novel combination therapies in colorectal cancer

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.

  2020cites this paper
• Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

  2020cites this paper
• Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer

  2020cites this paper
• Comprehensive review of targeted therapy for colorectal cancer

  2020cites this paper
• Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype

  2020cites this paper
• Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients

  2020cites this paper
• Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

  2020cites this paper
• Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report

  2020cites this paper
• Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets

  2020cites this paper
• Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study

  2019cites this paper
• Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

  2019cites this paper
• Systemic treatment for metastatic colorectal cancer in the era of precision medicine

  2019cites this paper
• Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

  2019cites this paper
• Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

  2019cites this paper
• Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

  2019cites this paper
• Adverse events in the treatment of colorectal cancer: Their use as predictive markers and impact on quality of life

  2019cites this paper
• The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

  2019cites this paper
• EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2‐mediated MAPK pathway activation in gastric cancer cells and avatar mice

  2019cites this paper
• Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy

  2019cites this paper
• Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

  2019cites this paper
• Pertuzumab and trastuzumab for HER2-amplified metastatic colorectal cancer: an updated report from MyPathway, a multicentre, open-label, phase 2a multiple basket study

  2019cites this paper
• Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

  2019cites this paper
• Resistance of Colorectal Tumors to Anti-EGFR Antibodies

  2018cites this paper
• Personalized Cancer Medicine: An Organoid Approach.

  2018cites this paper
• EVIR: Chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens

  2018cites this paper
• Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

  2018cites this paper
• HER2-targeted therapy: an emerging strategy in advanced colorectal cancer

  2018cites this paper
• EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

  2018cites this paper
• Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

  2018cites this paper
• HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features

  2018cites this paper
• The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

  2018cites this paper
• Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.

  2018cites this paper
• Computational Modeling of Drug Response and Pathway Activity in Colorectal Cancer with Missing Data Reconstruction and Subtype Analysis

  2018cites this paper
• Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.

  2018cites this paper
• Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer

  2018cites this paper
• Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.

  2018cites this paper
• Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines

  2018influential citation
• The Role of HER2 Testing in Advanced Colorectal Cancer

  2018cites this paper
• Dual-targeted nanomedicines for enhanced tumor treatment

  2018cites this paper
• Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.

  2017cites this paper
• Interrogating open issues in cancer precision medicine with patient-derived xenografts

  2017cites this paper
• Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2

  2017cites this paper
• A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy

  2017cites this paper
• Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.

  2017cites this paper
• Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.

  2017cites this paper
• Neues Target beim fortgeschrittenen kolorektalen Karzinom

  2016cites this paper
• The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.

  2016cites this paper
• Depression accelerates the development of gastric cancer through reactive oxygen species‑activated ABL1 (Review).

  2016cites this paper
• HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

  2016cites this paper
• Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines

  2016cites this paper
• Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?

  2016cites this paper
• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

  2016cites this paper
• Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.

  2016cites this paper
• EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.

  2016cites this paper
• Targeting HER2: precision oncology for colorectal cancer.

  2016cites this paper
• Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications

  2016cites this paper
• Scholarly Commons @ Baptist Health South Florida Scholarly Commons @ Baptist Health South Florida

  year unknowncites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper